Abstract PS2-02-29: Real world evidence of systemic therapy in hormone receptor positive advanced breast cancer (HR+ ABC) in Australia - ARORA Registry

Abstract BACKGROUND: The incorporation of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) into first line (1L) systemic treatment for patients with HR+ ABC is now standard practice and leads to improved survival. However, there is a paucity of data on uptake of standard therapies and their associated toxicities in the real-world setting. Here, we present updated results from the ARORA registry. METHODS: ARORA is a secondary data use study of Australian patients aged ≥18 years and diagnosed with HR+ ABC after 1 Jan 2020. Prospective data is captured on patient characteristics, disease course, systemic therapy sequencing and treatment outcomes in routine clinical practice. Database lock for analysis was 19 May 2025. RESULTS: Data was analysed from 457 patients at 17 sites, with a median follow-up of 38.8 months. Median age was 64 years (24% ≥75 years). 65.6% were ECOG 0-1 and 2.8% had a BRCA1/2 pathogenic variant. 44.2% had liver or lung metastases, and 19% had bone-only disease. 60.4% had relapsed metastatic disease. Of these, 9.1% and 46.7% had received neoadjuvant and adjuvant chemotherapy respectively following early stage disease, and 75.2% had received adjuvant endocrine therapy (ET). 44.5% relapsed within 12 months of stopping adjuvant ET. 9 patients (2%) did not receive any systemic therapy for ABC. Of the 448 patients on 1L therapy, 335 (74.8%) received CDK4/6i + ET, 67 (15%) received ET alone and 41 (9.1%) received chemotherapy. Clinician preference for 1L CDK4/6i was palbociclib (32.6%), followed by ribociclib (27.2%) and abemaciclib (11.2%). Patients who received 1L ET alone were older (median 79 vs 63 years, 62.7% vs 18.5% ≥75 years), with poorer performance status (44.8% vs 8.7% ECOG ≥2) and more co-morbidities (29.8% vs 10.5% Charlson index ≥2). Conversely, those who received 1L chemotherapy were younger (median 58 years, 7.3% ≥75 years), with better performance status (46.3% vs 37.9% ECOG 0) and fewer co-morbidities (92.7% vs 88.9% Charlson index <2). They were more likely to have visceral metastases compared to those on CDK4/6i + ET (58.5% vs 45.7%), particularly liver metastases (46.3% vs 19.1%). Median 1L progression-free survival with 1L CDK4/6i + ET was 33.9 months, consistent with the upper end reported in trials (23.8–33.6 months). Common reported toxicities with CDK4/6i were diarrhoea (62.2% abemaciclib vs 10% ribociclib vs 6.6% palbociclib), neutropenia (44.9% palbociclib vs 40.8% ribociclib vs 22.2% abemaciclib) and nausea/vomiting (28.3% ribociclib vs 22.2% abemaciclib vs 17.6% palbociclib). Hepatotoxicity occurred in 5.8% ribociclib vs 4.6% abemaciclib vs 0.7% palbociclib. 2.5% of patients on ribociclib had QTc prolongation. Pneumonitis occurred in 1 patient on each CDK4/6i. Treatment was stopped due to toxicity for 20.5% ribociclib, 18% abemaciclib and 12.3% palbociclib. At the time of database lock, 117 of 335 patients (34.9%) who received 1L CDK4/6i + ET had moved to second line (2L). 60 (51.3%) received chemotherapy alone, 39 (33.3%) received ET alone and 5 (4.3%) received targeted therapies (e.g. mTOR or PIK3CA inhibitors). Capecitabine was the most common chemotherapy regimen (44/60, 73.3%). Median 2L duration of treatment was longest with targeted therapies (6.8 months), followed by chemotherapy (4.8 months) and ET alone (3.3 months). Overall survival data is immature. CONCLUSION: While CDK4/6i + ET is recommended as 1L treatment of HR+ ABC, three-quarters of routinely treated patients received this combination. A substantial minority received ET alone or chemotherapy. Age, ECOG, co-morbidity burden and presence of visceral disease remain major determinants of treatment choice. CDK4/6i toxicity profiles are consistent with trials. In 2L, chemotherapy is preferred in over half of patients, but clinical outcomes trend better if targeted therapies are available. Citation Format: M. Li, V. Wong, S. Baron-Hay, R. de Boer, F. Boyle, A. Campbell, I. M. Collins, K. Cuff, L. Gately, C. Georgiou, S. Greenberg, E. Jude, B. Karki, K. Mok, C. Morton, L. Nott, M. Nottage, N. Rainey, J. Torres, I. Tung, P. Gibbs, S. Lok. Real world evidence of systemic therapy in hormone receptor positive advanced breast cancer (HR+ ABC) in Australia - ARORA Registry [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS2-02-29.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-02-17
DOI
https://doi.org/10.1158/1557-3265.sabcs25-ps2-02-29
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract PS2-02-29: Real world evidence of systemic therapy in hormone receptor positive advanced breast cancer (HR+ ABC) in Australia - ARORA Registry

Chloe L. Georgiou, Michelle Nottage, Iris Tung, Lucy Gately et al.
Clinical Cancer Research
Advanced Breast Cancer Therapies
article

Abstract PS2-02-29: Real world evidence of systemic therapy in hormone receptor positive advanced breast cancer (HR+ ABC) in Australia - ARORA Registry

Chloe L. Georgiou, Michelle Nottage, Iris Tung, Lucy Gately, Vanessa Wong, SW Lok, Bhesh R. Karki, Sally Greenberg, Katharine Cuff, Natalie Rainey, Javier Torres, Kelly Mok, Evon Jude, C. Morton, P. Gibbs, M. Li, R. de Boer, I. M. Collins, F. Boyle, S. Baron-Hay, L. Nott, A. Campbell
article en

Abstract

Abstract BACKGROUND: The incorporation of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) into first line (1L) systemic treatment for patients with HR+ ABC is now standard practice and leads to improved survival. However, there is a paucity of data on uptake of standard therapies and their associated toxicities in the real-world setting. Here, we present updated results from the ARORA registry. METHODS: ARORA is a secondary data use study of Australian patients aged ≥18 years and diagnosed with HR+ ABC after 1 Jan 2020. Prospective data is captured on patient characteristics, disease course, systemic therapy sequencing and treatment outcomes in routine clinical practice. Database lock for analysis was 19 May 2025. RESULTS: Data was analysed from 457 patients at 17 sites, with a median follow-up of 38.8 months. Median age was 64 years (24% ≥75 years). 65.6% were ECOG 0-1 and 2.8% had a BRCA1/2 pathogenic variant. 44.2% had liver or lung metastases, and 19% had bone-only disease. 60.4% had relapsed metastatic disease. Of these, 9.1% and 46.7% had received neoadjuvant and adjuvant chemotherapy respectively following early stage disease, and 75.2% had received adjuvant endocrine therapy (ET). 44.5% relapsed within 12 months of stopping adjuvant ET. 9 patients (2%) did not receive any systemic therapy for ABC. Of the 448 patients on 1L therapy, 335 (74.8%) received CDK4/6i + ET, 67 (15%) received ET alone and 41 (9.1%) received chemotherapy. Clinician preference for 1L CDK4/6i was palbociclib (32.6%), followed by ribociclib (27.2%) and abemaciclib (11.2%). Patients who received 1L ET alone were older (median 79 vs 63 years, 62.7% vs 18.5% ≥75 years), with poorer performance status (44.8% vs 8.7% ECOG ≥2) and more co-morbidities (29.8% vs 10.5% Charlson index ≥2). Conversely, those who received 1L chemotherapy were younger (median 58 years, 7.3% ≥75 years), with better performance status (46.3% vs 37.9% ECOG 0) and fewer co-morbidities (92.7% vs 88.9% Charlson index <2). They were more likely to have visceral metastases compared to those on CDK4/6i + ET (58.5% vs 45.7%), particularly liver metastases (46.3% vs 19.1%). Median 1L progression-free survival with 1L CDK4/6i + ET was 33.9 months, consistent with the upper end reported in trials (23.8–33.6 months). Common reported toxicities with CDK4/6i were diarrhoea (62.2% abemaciclib vs 10% ribociclib vs 6.6% palbociclib), neutropenia (44.9% palbociclib vs 40.8% ribociclib vs 22.2% abemaciclib) and nausea/vomiting (28.3% ribociclib vs 22.2% abemaciclib vs 17.6% palbociclib). Hepatotoxicity occurred in 5.8% ribociclib vs 4.6% abemaciclib vs 0.7% palbociclib. 2.5% of patients on ribociclib had QTc prolongation. Pneumonitis occurred in 1 patient on each CDK4/6i. Treatment was stopped due to toxicity for 20.5% ribociclib, 18% abemaciclib and 12.3% palbociclib. At the time of database lock, 117 of 335 patients (34.9%) who received 1L CDK4/6i + ET had moved to second line (2L). 60 (51.3%) received chemotherapy alone, 39 (33.3%) received ET alone and 5 (4.3%) received targeted therapies (e.g. mTOR or PIK3CA inhibitors). Capecitabine was the most common chemotherapy regimen (44/60, 73.3%). Median 2L duration of treatment was longest with targeted therapies (6.8 months), followed by chemotherapy (4.8 months) and ET alone (3.3 months). Overall survival data is immature. CONCLUSION: While CDK4/6i + ET is recommended as 1L treatment of HR+ ABC, three-quarters of routinely treated patients received this combination. A substantial minority received ET alone or chemotherapy. Age, ECOG, co-morbidity burden and presence of visceral disease remain major determinants of treatment choice. CDK4/6i toxicity profiles are consistent with trials. In 2L, chemotherapy is preferred in over half of patients, but clinical outcomes trend better if targeted therapies are available. Citation Format: M. Li, V. Wong, S. Baron-Hay, R. de Boer, F. Boyle, A. Campbell, I. M. Collins, K. Cuff, L. Gately, C. Georgiou, S. Greenberg, E. Jude, B. Karki, K. Mok, C. Morton, L. Nott, M. Nottage, N. Rainey, J. Torres, I. Tung, P. Gibbs, S. Lok. Real world evidence of systemic therapy in hormone receptor positive advanced breast cancer (HR+ ABC) in Australia - ARORA Registry [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS2-02-29.

Clinical Cancer ResearchVol. 32(4_Supplement)
Goulburn Valley Health (AU), Mater Health Services (AU), Walter and Eliza Hall Institute of Medical Research (AU), Royal Brisbane and Women's Hospital (AU), Toowoomba Hospital (AU), Liverpool Hospital (AU), Cairns Hospital (AU), Princess Alexandra Hospital (AU), Royal Hobart Hospital (AU), St Vincent's Hospital Melbourne (AU), Eastern Health (AU), St Vincent’s Private Hospital Sydney (AU), Western Health (AU), Sonic Healthcare (Germany) (DE), Northern Cancer Institute (AU), Bendigo Health (AU), Alfred Health (AU), Austin Health (AU)
Good health and well-being
Openalex Percentile: Top 51%
Advanced Breast Cancer Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.